| __timestamp | Intra-Cellular Therapies, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21226345 | 5758000 |
| Thursday, January 1, 2015 | 139626 | 8423000 |
| Friday, January 1, 2016 | 93831530 | 11986000 |
| Sunday, January 1, 2017 | 79419009 | 15215000 |
| Monday, January 1, 2018 | 368673 | 15356000 |
| Tuesday, January 1, 2019 | 477121 | 16660000 |
| Wednesday, January 1, 2020 | 1895029 | 52459000 |
| Friday, January 1, 2021 | 8034589 | 75061000 |
| Saturday, January 1, 2022 | 20443000 | 87221000 |
| Sunday, January 1, 2023 | 33745000 | 83779000 |
Data in motion
In the dynamic world of biopharmaceuticals, understanding cost efficiency is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Intra-Cellular Therapies, Inc. and Supernus Pharmaceuticals, Inc. from 2014 to 2023.
Intra-Cellular Therapies, Inc. has shown a remarkable increase in cost efficiency, with a 59% reduction in cost of revenue from 2016 to 2023. In contrast, Supernus Pharmaceuticals, Inc. experienced a 45% increase in costs over the same period. Notably, 2020 marked a significant year for Supernus, with costs peaking at 52 million, reflecting a strategic shift in operations.
These trends highlight the importance of strategic financial management in the biopharmaceutical sector. As companies navigate the complexities of drug development and market competition, cost efficiency remains a pivotal factor in sustaining growth and profitability.
Analyzing Cost of Revenue: Novo Nordisk A/S and Intra-Cellular Therapies, Inc.
Cost of Revenue: Key Insights for Merck & Co., Inc. and Intra-Cellular Therapies, Inc.
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Intra-Cellular Therapies, Inc.
Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Supernus Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Supernus Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
Intra-Cellular Therapies, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Walgreens Boots Alliance, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses
Cost Insights: Breaking Down Pharming Group N.V. and Supernus Pharmaceuticals, Inc.'s Expenses
Corcept Therapeutics Incorporated vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Supernus Pharmaceuticals, Inc. vs Wave Life Sciences Ltd.
Comparing Cost of Revenue Efficiency: Supernus Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.